ES2671248T3 - Métodos para tratar el cáncer que comprenden un guiado por NQO1 - Google Patents

Métodos para tratar el cáncer que comprenden un guiado por NQO1 Download PDF

Info

Publication number
ES2671248T3
ES2671248T3 ES11827555T ES11827555T ES2671248T3 ES 2671248 T3 ES2671248 T3 ES 2671248T3 ES 11827555 T ES11827555 T ES 11827555T ES 11827555 T ES11827555 T ES 11827555T ES 2671248 T3 ES2671248 T3 ES 2671248T3
Authority
ES
Spain
Prior art keywords
nqo1
individual
treatment
cancer
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11827555T
Other languages
English (en)
Inventor
David Boothman
Jinming Gao
Erik Bey
Ying Dong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of ES2671248T3 publication Critical patent/ES2671248T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para determinar si un individuo con cáncer es adecuado para un tratamiento con un fármaco bioactivable por NQO1 o predecir la sensibilidad de un individuo con cáncer a un tratamiento con un fármaco bioactivable por NQO1, en donde: (i) el método es para determinar si un individuo con cáncer es adecuado para un tratamiento con un fármaco bioactivable por NQO1 y comprende medir el nivel proteínico de la expresión de NQO1 y la expresión de catalasa en células cancerosas en una muestra del individuo, indicando una razón del nivel de NQO1 con respecto al nivel de catalasa en las células cancerosas del individuo al menos aproximadamente 50 veces mayor que la razón de un tejido normal que el individuo es adecuado para el tratamiento; o (ii) el método es para predecir la sensibilidad de un individuo con cáncer a un tratamiento con un fármaco bioactivable por NQO1 y comprende medir el nivel proteínico de la expresión de NQO1 y la expresión de catalasa en las células cancerosas en una muestra del individuo, indicando una razón del nivel de NQO1 con respecto al nivel de catalasa en las células cancerosas del individuo al menos aproximadamente 50 veces mayor que la razón de un tejido normal que es más probable que el individuo sea sensible al tratamiento.
ES11827555T 2010-09-22 2011-09-22 Métodos para tratar el cáncer que comprenden un guiado por NQO1 Active ES2671248T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38541110P 2010-09-22 2010-09-22
PCT/US2011/052801 WO2012040492A1 (en) 2010-09-22 2011-09-22 Methods of treating cancer comprising targeting nqo1

Publications (1)

Publication Number Publication Date
ES2671248T3 true ES2671248T3 (es) 2018-06-05

Family

ID=45874170

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11827555T Active ES2671248T3 (es) 2010-09-22 2011-09-22 Métodos para tratar el cáncer que comprenden un guiado por NQO1

Country Status (10)

Country Link
US (1) US9469878B2 (es)
EP (1) EP2619331B1 (es)
DK (1) DK2619331T3 (es)
ES (1) ES2671248T3 (es)
HU (1) HUE037382T2 (es)
NO (1) NO2619331T3 (es)
PL (1) PL2619331T3 (es)
PT (1) PT2619331T (es)
TR (1) TR201807363T4 (es)
WO (1) WO2012040492A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039247T2 (hu) 2011-10-14 2018-12-28 Univ Illinois Vegyületek és tumorellenes NQO1-szubsztrátok
CA2909091C (en) * 2013-04-09 2021-11-02 The Board Of Trustees Of The University Of Illinois Tumor-selective combination therapy
CN103667447A (zh) * 2013-11-04 2014-03-26 武汉艾迪康医学检验所有限公司 用于检测nqo1基因多态性的引物、试剂盒及其在病理检测上的应用
WO2019156684A1 (en) * 2018-02-12 2019-08-15 Solugen, Inc. Hydrogen peroxide production method, system, and apparatus
MX2021011301A (es) * 2019-03-18 2022-01-19 Univ Texas Terapia combinada especifica contra tumores.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342054T1 (de) 1999-04-14 2006-11-15 Dana Farber Cancer Inst Inc Verfahren und zusammansetzung zur behandlung von krebs
ES2341922T3 (es) * 2001-11-01 2010-06-29 Spectrum Pharmaceuticals, Inc. Composiciones medicas para el tratamiento intravesical de cancer de vejiga.
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
EP1877097B1 (en) 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
WO2007092963A1 (en) * 2006-02-09 2007-08-16 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
WO2008106129A2 (en) 2007-02-26 2008-09-04 Wisconsin Alumni Research Foundation Polymeric micelles for combination drug delivery
AU2011306076B2 (en) 2010-09-22 2015-05-07 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof

Also Published As

Publication number Publication date
PL2619331T3 (pl) 2018-10-31
NO2619331T3 (es) 2018-07-28
EP2619331B1 (en) 2018-02-28
US20130253046A1 (en) 2013-09-26
WO2012040492A1 (en) 2012-03-29
TR201807363T4 (tr) 2018-06-21
EP2619331A1 (en) 2013-07-31
PT2619331T (pt) 2018-06-01
DK2619331T3 (en) 2018-06-06
EP2619331A4 (en) 2014-03-05
HUE037382T2 (hu) 2018-08-28
US9469878B2 (en) 2016-10-18

Similar Documents

Publication Publication Date Title
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
MA32630B1 (fr) Procedes, systemes et produits pour prevoir une reponse des cellules tumorales a un agent therapeutique et traitement d'un patient conformement a la reponse prevue
GB2467467A (en) Taz/wwtr1 for diagnosis and treatment of cancer
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
ES2671248T3 (es) Métodos para tratar el cáncer que comprenden un guiado por NQO1
ES2656962T3 (es) Métodos para evaluar la receptividad del endometrio de una paciente
DK2848938T3 (da) Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
BRPI0807927A2 (pt) Métodos para determinar uma susceptibilidade a doença cardiovascular em um indivíduo humano, de identificação de um marcador para uso para avaliar susceptibilidade a doença cardiovascular, para genotipar uma amostra de ácido nucleico, para avaliar um indivíduo para probabilidade de resposta a um agente terapêutico, para predizer prognóstico de um indivíduo diagnosticado com doença cardiovascular, e para monitorar progresso de tratamento de um indivíduo passando por tratamento para doença cardiovascular, kit para avaliar susceptibilidade a doença cardiovascular em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para doença cardiovascular em um indivíduo humano
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
MX2010008835A (es) Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades.
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
AR084723A1 (es) microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
AR065150A1 (es) Metodos y dispositivos para el diagnostico de apendicitis
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
PE20141565A1 (es) Metodos para detectar papilomavirus humano y proporcionar pronostico para carcinoma de celulas escamosas de cabeza y cuello
WO2009075797A3 (en) Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
BR112016024143A2 (pt) tratamento de câncer
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
WO2015048336A3 (en) Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzhimer's disease (psad)
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits